

MarÃ- a Pilar Ballester

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1042106/publications.pdf>

Version: 2024-02-01

31
papers

239
citations

1039406

9
h-index

1058022

14
g-index

33
all docs

33
docs citations

33
times ranked

280
citing authors

#	ARTICLE	IF	CITATIONS
1	Public health policies and alcohol-related liver disease. <i>JHEP Reports</i> , 2019, 1, 403-413.	2.6	33
2	Enfermedad de Crohn. <i>Medicina Clínica</i> , 2018, 151, 26-33.	0.3	26
3	Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease. <i>Radiology</i> , 2022, 302, 345-354.	3.6	25
4	Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. <i>Journal of Translational Medicine</i> , 2019, 17, 293.	1.8	16
5	Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. <i>Scientific Reports</i> , 2020, 10, 17774.	1.6	14
6	Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2154.	1.0	13
7	Long-term follow-up of patients treated with aminosalicilates for ulcerative colitis: Predictive factors of response: An observational case-control study. <i>United European Gastroenterology Journal</i> , 2019, 7, 1042-1050.	1.6	12
8	A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2806.	1.0	11
9	Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1402-1413.	1.9	9
10	Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	1.9	8
11	Alcohol and Acute-on-Chronic Liver Failure. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1360-1370.	0.4	8
12	Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. <i>World Journal of Hepatology</i> , 2017, 9, 161.	0.8	7
13	Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. <i>Scientific Reports</i> , 2022, 12, 2463.	1.6	7
14	Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1053-1059.	1.0	6
15	Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function. <i>Journal of Clinical Medicine</i> , 2021, 10, 239.	1.0	6
16	Risk factors and management strategies associated with non-response to aminosalicilates for maintenance treatment in ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 447-453.	0.1	6
17	Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 316-317.	0.1	6
18	Disease severity and treatment requirements in familial inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1197-1205.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Serum cholesterol predicts transplant-free survival in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt. <i>Digestive and Liver Disease</i> , 2021, 53, 1596-1602.	0.4	4
20	Transjugular intrahepatic portosystemic shunt reduces hospital care burden in patients with decompensated cirrhosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1519-1527.	1.0	3
21	Surgical treatment of an intraductal papillary mucinous neoplasm of the biliary tract diagnosed by SpyGlass [®] 1/2. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 45-47.	0.1	2
22	Sal1910 Family Association In Inflammatory Bowel Disease And Its Treatment Requirements. <i>Gastroenterology</i> , 2016, 150, S400.	0.6	0
23	Phenotypic Characteristics can Predict the Need of Adjuvant Therapy in Addition to Aminosalicylates for Maintenance of Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2017, 152, S753.	0.6	0
24	Bowel perforation after pneumatic dilatation: Management with fully covered self-expandable metallic stent. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 401-402.	0.2	0
25	Mo1765 "Real-Life Experience with Long-Term Maintenance of Golimumab in Ulcerative Colitis Patients. <i>Gastroenterology</i> , 2019, 156, S-831.	0.6	0
26	FRI-118-Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, e439.	1.8	0
27	SAT-085-Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, e665.	1.8	0
28	P: 55"Decreased Cognitive Performance Is Associated With Reduced Resting State Connectivity and Gray Matter Atrophy in Patients With Minimal Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2019, 114, S27-S28.	0.2	0
29	Characterization of alterations in mechanical, thermal and pain sensitivity in cirrhotic patients with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2020, 73, S700-S701.	1.8	0
30	Thiopurine adherence: high prevalence with low impact in UC outcomes. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.1	0
31	A rare case of acute cholangitis after endoscopic ampullectomy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 503-504.	0.1	0